FCP levels identified T2DM people experiencing different responses to basal insulin Gla‐100. A low FCP identifies a markedly insulin‐deficient, insulin‐sensitive subgroup/phenotype with an enhanced risk of hypoglycaemia, which requires a low initial basal insulin dose, cautious titration and earlier addition of prandial glucose‐lowering therapy (Diabetes, Obesity and Metabolism)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
This comprehensive review covers the historical background, physiology, application in type 2 diabetes, novel uses, cardiovascular benefits, side effects and contraindications of sodium-glucose cotransporter-2 (SGLT2) inhibitors (Diabetes, Metabolic Syndrome and Obesity)
Diabetic foot problems: prevention and management
NICE: In October 2019, we reviewed the evidence for antimicrobial prescribing for diabetic foot infections and updated the recommendations
National Pregnancy in Diabetes Audit Report 2018
The National Pregnancy in Diabetes Audit (NPID) is a workstream of the National Diabetes Audit (NDA) and is managed by NHS Digital under an agreement with the Healthcare Quality Improvement Partnership (HQIP) on behalf of NHS England and the Welsh Government
New capsule can orally deliver drugs that usually have to be injected
Coated pill carries microneedles that deliver insulin and other drugs to the lining of the small intestine (MIT)
Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis
Our findings suggest that disparity in glycaemic control, diabetes-related monitoring, and prescription of newer therapies remains a challenge in diabetes care. Both SES and ethnicity were important determinants of inequality (PLOS Medicine)
Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes
In elderly individuals with T2D, the effect of glycaemic control (measured by HbA1c) on all‐cause mortality depended on the duration of diabetes. Of particular clinical importance, we found that strict glycaemic control was associated with an increased risk of death among individuals with long (>5 years) diabetes duration (Diabetes, Obesity and Metabolism)
Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures
Greater glucose-stimulated GLP-1 responses were associated with clinically relevant lower central and peripheral blood pressures, consistent with beneficial effects on the cardiovascular system and reduced risk of CVD and mortality (Cardiovascular Diabetology)
Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion
The DAPA-HF trial substantially extends the benefits of SGLT2 inhibitors in slowing the evolution and progression of heart failure, particularly in patients with a reduced ejection fraction (Cardiovascular Diabetology)
Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
Approximately one-third of patients with T2DM in the UK have concomitant CVD (Diabetes Therapy)
Short term optimization of glycaemic control using insulin improves sympatho-vagal tone activities in patients with type 2 diabetes
The optimization of glycaemic control using a basal plus insulin regimen while inducing a significant reduction in glycated hemoglobin, significantly improves 24-hour ambulatory ECG derived sympathetic and parasympathetic activities. This suggests that tight glycaemic control using insulin may revert cardiac autonomic neuropathy in type 2 diabetes mellitus patients (Diabetes Research and Clinical Practice)
Behaviour change, weight loss and remission of Type 2 diabetes: a community‐based prospective cohort study
In a population‐based sample of adults with screen‐detected Type 2 diabetes, weight loss of ≥10% early in the disease trajectory was associated with a doubling of the likelihood of remission at 5 years (Diabetic Medicine)
Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
Combined GIP- and GLP1R activators have the potential to become a treatment option for patients with type 2 diabetes (Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy)
Type 1 Diabetes is Associated with an Increase in Cholesterol Absorption Markers but a Decrease in Cholesterol Synthesis Markers in a Young Adult Population
Plasma markers suggest that cholesterol absorption is increased whereas cholesterol synthesis is decreased in type 1 diabetes. Further studies to address the impact of these changes on the relative efficacy of cholesterol absorption and synthesis inhibitors in subjects with type 1 diabetes are urgently needed (Journal of Clinical Lipidology)
Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents
Renal glucosuria is associated with lower body weight and obesity as well as with lower rates of elevated systolic blood pressure (Cardiovascular Diabetology)
How to perform better intervention to prevent and control diabetic retinopathy among patients with type 2 diabetes: A meta-analysis of randomized controlled trials
We found that multifactorial interventions can significantly reduce the risk of developing DR and its progression among patients with type 2 diabetes. More importantly, we found all these multifactorial interventions contained individualization of targets and communication between health professionals and patients, suggesting ophthalmologists and diabetes health professionals should work together with patients to set more individualized targets while taking into account multiple factors so as to achieve optimal effect in DR prevention and control (Diabetes Research and Clinical Practice)
Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function
Among patients with diabetes and reduced kidney function persisting with monotherapy, treatment with metformin, compared with a sulfonylurea, was associated with a lower risk of MACE (JAMA)
Type 2 Diabetes Mellitus and Menopausal Hormone Therapy: An Update
Although in the past women with T2DM would be excluded from MHT, nowadays there is strong evidence to support an individualised approach after careful evaluation of their CVD risk (Diabetes Therapy)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes – The CAROLINA Randomized Clinical Trial
Among adults with relatively early type 2 diabetes and elevated cardiovascular risk, the use of linagliptin compared with glimepiride over a median 6.3 years resulted in a noninferior risk of a composite cardiovascular outcome (JAMA)
Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study
rtCGM was superior to SMBG in reducing A1C, hypoglycemia, and other end points in individuals with T1D regardless of their insulin delivery method. rtCGM+MDI can be considered an equivalent but lower-cost alternative to sensor-augmented insulin pump therapy and superior to treatment with SMBG+MDI or SMBG+CSII therapy (Diabetes Care)
- 1
- 2
- 3
- …
- 187
- Next Page »
Glycosmedia is also available as an App: